Gainers
- Dynatronics, Inc. DYNT shares increased by 239.4% to $4.09 during Friday's pre-market session.
- Ritter Pharmaceuticals, Inc. RTTR shares rose 182.0% to $0.80.
- Altimmune, Inc. ALT shares surged 110.8% to $3.71.
- Allied Healthcare Prods, Inc. AHPI stock increased by 91.4% to $29.70.
- Trinity Biotech, Inc. TRIB shares rose 58.9% to $1.70.
- Correvio Pharma, Inc. CORV shares moved upwards by 53.4% to $0.47. According to the most recent rating by H.C. Wainwright, on December 11, the current rating is at Neutral.
- Guardion Health Sciences, Inc. GHSI stock surged 46.5% to $0.69.
- Trillium Therapeutics, Inc. TRIL shares surged 41.9% to $4.40.
- BOQI International, Inc. BIMI shares rose 39.8% to $5.90.
- Vaxart, Inc. VXRT stock surged 38.5% to $3.42.
- Verastem, Inc. VSTM stock moved upwards by 35.6% to $2.59.
- OpGen, Inc. OPGN stock rose 29.9% to $2.65.
- Sangamo Therapeutics, Inc. SGMO stock increased by 29.8% to $8.65.
- Titan Pharmaceuticals, Inc. TTNP shares increased by 29.0% to $0.27.
- Novavax, Inc. NVAX stock moved upwards by 26.7% to $14.95. The most recent rating by B. Riley FBR, on February 28, is at Buy, with a price target of $16.00.
- Co-Diagnostics, Inc. CODX stock surged 23.4% to $19.70. The most recent rating by HC Wainwright & Co., on February 24, is at Buy, with a price target of $4.00.
- Forty Seven, Inc. FTSV shares surged 23.0% to $60.00. The most recent rating by Mizuho, on February 12, is at Buy, with a price target of $53.00.
- Vir Biotechnology, Inc. VIR stock rose 21.6% to $73.19. The most recent rating by JP Morgan, on February 04, is at Neutral, with a price target of $26.00.
- China SXT Pharmaceuticals, Inc. SXTC stock surged 20.6% to $1.23.
- Assertio Therapeutics, Inc. ASRT shares moved upwards by 19.1% to $1.25.
- Lianluo Smart, Inc. LLIT shares moved upwards by 18.4% to $0.91.
- Beyond Air, Inc. XAIR shares surged 18.3% to $8.65.
- Cocrystal Pharma, Inc. COCP shares surged 17.2% to $1.50.
- Meridian Bioscience, Inc. VIVO shares increased by 13.4% to $9.25.
- Happiness Biotech, Inc. HAPP shares surged 13.3% to $5.86.
Losers
- Novan, Inc. NOVN stock plummeted 35.3% to $0.22 during Friday's pre-market session. The most recent rating by H.C. Wainwright, on January 06, is at Buy, with a price target of $1.50.
- Diffusion Pharmaceuticals, Inc. DFFN stock decreased by 13.0% to $0.31. The most recent rating by H.C. Wainwright, on December 18, is at Buy, with a price target of $3.50.
- PAVmed, Inc. PAVM shares decreased by 11.2% to $2.15.
- Kadmon Holdings, Inc. KDMN stock plummeted 10.3% to $4.00. The most recent rating by Nomura Instinet, on January 10, is at Buy, with a price target of $10.00.
- Acasti Pharma, Inc. ACST shares plummeted 9.8% to $0.40. The most recent rating by H.C. Wainwright, on February 18, is at Buy, with a price target of $3.00.
- Moderna, Inc. MRNA stock fell 8.8% to $23.86. The most recent rating by Needham, on February 26, is at Buy, with a price target of $35.00.
- Viveve Medical, Inc. VIVE stock plummeted 8.5% to $1.08. According to the most recent rating by Ladenburg Thalmann, on December 03, the current rating is at Buy.
- Five Prime Therapeutics, Inc. FPRX stock plummeted 7.4% to $4.00. According to the most recent rating by JP Morgan, on February 28, the current rating is at Underweight.
- Celldex Therapeutics, Inc. CLDX shares plummeted 7.4% to $2.51. The most recent rating by Cantor Fitzgerald, on February 21, is at Overweight, with a price target of $8.00.
- Zosano Pharma, Inc. ZSAN stock declined 7.2% to $0.65.
- Genprex, Inc. GNPX stock fell 7.0% to $4.35.
- Advaxis, Inc. ADXS shares fell 7.0% to $0.72.
- Onconova Therapeutics, Inc. ONTX stock decreased by 6.4% to $0.44.
- Cyclacel Pharmaceuticals, Inc. CYCC stock declined 6.4% to $0.52.
- CHF Solutions, Inc. CHFS shares fell 6.3% to $0.32.
- NantKwest, Inc. NK stock plummeted 6.2% to $4.39.
- Nabriva Therapeutics, Inc. NBRV stock fell 6.2% to $1.21.
- argenx, Inc. ARGX stock plummeted 6.0% to $135.00. According to the most recent rating by B of A Securities, on February 10, the current rating is at Buy.
- Heat Biologics, Inc. HTBX stock declined 5.7% to $0.20. The most recent rating by Maxim Group, on February 06, is at Buy, with a price target of $1.00.
- Achieve Life Sciences, Inc. ACHV shares fell 5.6% to $0.44. The most recent rating by H.C. Wainwright, on February 25, is at Buy, with a price target of $2.00.
- OrganiGram Holdings, Inc. OGI shares plummeted 5.4% to $2.10. According to the most recent rating by Raymond James, on January 09, the current rating is at Market Perform.
- Amarin Corp, Inc. AMRN shares decreased by 5.2% to $13.90. The most recent rating by Oppenheimer, on February 26, is at Underperform, with a price target of $12.00.
- Agile Therapeutics, Inc. AGRX shares fell 5.1% to $2.60. The most recent rating by H.C. Wainwright, on February 18, is at Buy, with a price target of $7.00.
- Grifols, Inc. GRFS stock plummeted 5.0% to $22.30.
- TherapeuticsMD, Inc. TXMD shares decreased by 4.8% to $1.58. The most recent rating by H.C. Wainwright, on February 21, is at Buy, with a price target of $6.00.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in